Chargement en cours...

Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia.

Recombinant human erythropoietin (rHuEPO) has been advocated for the treatment of anaemia in patients submitted to cancer chemotherapy. We used decision analysis to compare the cost-effectiveness of rHuEPO supplemented with red blood cell (RBC) transfusions with conventional treatment with RBC trans...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Barosi, G., Marchetti, M., Liberato, N. L.
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group|1 1998
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2062982/
https://ncbi.nlm.nih.gov/pubmed/9743301
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!